IRVINE, Calif.--(BUSINESS WIRE)--
Khang & Khang LLP (the “Firm”) announces a class action lawsuit against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Investors who purchased or otherwise acquired shares between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 3, 2017 lead plaintiff motion deadline.
If you purchased shares of DaVita during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, DaVita made false and/or misleading statements and/or failed to disclose: that DaVita purposefully steered patients into unnecessary insurance plans in order to maximize profits; that DaVita was using the American Kidney Fund as a vehicle to facilitate these improper practices; that the Company’s revenues and profits were illegally obtained; that DaVita lacked effective internal controls over financial reporting; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information reached the public, the stock price of DaVita fell.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006365/en/
